Atrial Fibrillation Clinical Trials in Durham, North Carolina

5 studies are recruiting for atrial fibrillation in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

   The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called el…

   Stage

   Phase 2

   Ages

   18 to 85

   Site

   Duke University Hospital - Cardiology, Durham, North Carolina

   Locations

   29 in total

   Run by

   Bayer

   See if you can join NCT07625215 on ClinicalTrials.gov

2. PULSED AF Post-Approval Study

   PULSED AF PAS is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke University Medical Center (DUMC), Durham, North Carolina

   Locations

   23 in total

   Run by

   Medtronic Cardiac Ablation Solutions

   See if you can join NCT06578104 on ClinicalTrials.gov

3. A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

   A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Duke Univ Medical Center, Durham, North Carolina

   Locations

   40 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT07217067 on ClinicalTrials.gov

4. Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

   The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated c…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   106 in total

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT04045665 on ClinicalTrials.gov

5. Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

   Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in b…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke University Hospital, Durham, North Carolina

   Locations

   187 in total

   Run by

   Yale University

   See if you can join NCT03907046 on ClinicalTrials.gov